Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW-Scz-1: Phase 2 study of adjunctive brenipatide in adults with schizophrenia
CTR20260821Phase 2Active
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Brenipatide adjunctive therapy with Placebo adjunctive therapy (2 arms). Started Mar 2026; status: active.
02
Drugs
brenipatide
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20260821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260821.